Investors and Media

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases.

Recent News

Apr 18, 2017Idera Pharmaceuticals Announces Organizational UpdateRead MoreApr 11, 2017Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic MelanomaRead MoreApr 05, 2017Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual MeetingRead More

Upcoming Events

There are currently no events scheduled.


There are currently no items available.
Data provided by Nasdaq. Minimum 15 minutes delayed.